公开(公告)号：US20240150413A1

公开(公告)日：2024-05-09

申请号：US18549951

申请日：2022-03-11

Applicant: Massachusetts Institute of Technology

Inventor： Alexi G. Choueiri ,  Yong Qian ,  Bowen Li ,  Robert S. Langer ,  Daniel G. Anderson ,  Edward S. Boyden

IPC: C07K14/005 ,  A61K38/16 ,  A61K38/46 ,  A61P31/14 ,  C12N9/22

CPC classification number: C07K14/005 ,  A61K38/162 ,  A61K38/465 ,  A61P31/14 ,  C12N9/22 ,  C07K2319/735 ,  C12N2770/20022 ,  C12N2770/20033

Abstract: In aspects, the invention provides novel compositions and methods for dominant inhibition of viral infection.

公开(公告)号：US20250049714A1

公开(公告)日：2025-02-13

申请号：US18717095

申请日：2022-12-08

Applicant: Massachusetts Institute of Technology

Inventor： Daniel Griffith Anderson ,  Luke Hyunsik Rhym ,  Bowen Li ,  Akiva Gordon ,  Manan Rajith Singh ,  Jacob Witten

IPC: A61K9/127 ,  A61K9/00 ,  A61K9/16 ,  A61K9/51 ,  A61K31/7105 ,  A61K31/711 ,  C07C229/12 ,  C07C229/16 ,  C07D207/06 ,  C07D213/38 ,  C07D255/02 ,  C07D295/13 ,  C12N15/88

Abstract: Provided herein are compounds, such as compounds of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, and isotopically labeled derivatives thereof, and compositions, methods, uses, and kits thereof. The compounds provided herein are lipids useful for delivery of polynucleotides, such as mRNA, for the treatment and/or prevention of various diseases and conditions (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, liver disease, spleen disease, lung disease, painful condition, psychiatric disorder, musculoskeletal disease, a metabolic disorder, inflammatory disease, or autoimmune disease).

公开(公告)号：US20230321230A1

公开(公告)日：2023-10-12

申请号：US18190068

申请日：2023-03-24

Applicant: Massachusetts Institute of Technology

Inventor： Bowen Li ,  Allen Jiang ,  Robert S. Langer ,  Daniel G. Anderson

IPC: A61K39/215 ,  C07K14/47 ,  A61K39/39 ,  C07K14/005

CPC classification number: A61K39/39 ,  A61K39/215 ,  C07K14/005 ,  C07K14/472 ,  A61K2039/53

Abstract: Provided herein are, in various embodiments, methods and compositions comprising polynucleotides (e.g., mRNA) for eliciting an immune response. In certain embodiments, the disclosure provides for methods and compositions for enhancing efficacy of infectious disease treatment (e.g., mRNA vaccines). In still further embodiments, the disclosure provides methods and compositions for enhancing one or more vaccines, such as SARS-CoV-2 mRNA vaccines.

公开(公告)号：US20250064938A1

公开(公告)日：2025-02-27

申请号：US18725289

申请日：2023-01-03

Applicant: Massachusetts Institute of Technology

Inventor： Daniel Griffith Anderson ,  Bowen Li ,  Akiva Gordon ,  Idris Raji

IPC: A61K47/54 ,  A61K9/127 ,  A61K31/7105 ,  A61K48/00 ,  C07C233/47 ,  C07D211/14 ,  C07D231/12 ,  C07D233/61 ,  C07D243/08 ,  C07D295/13 ,  C12N15/113

Abstract: Provided herein are lipid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipid compounds, compositions, or formulations for treating and/or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a tissue or cell in a subject (e.g., a liver, lung, or spleen tissue/cell).